Endovascular aneurysm repair

Endologix Appoints Mike Mathias as Chief Commercial Officer

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, TAVR, MD, Strategic planning, MBA, Percutaneous aortic valve replacement, University, Vascular disease, Peripheral artery disease, Organization, Medtronic, EVAR, Endovascular aneurysm repair

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.
  • With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, Mike brings a wealth of experience and a proven track record of success to Endologix.
  • Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans.
  • In response to his new role, Mike Mathias shared, "Joining Endologix at such a critical juncture is an honor.

Astute Imaging and Nectero Medical to Collaborate in Groundbreaking Aortic Aneurysm Trial

Retrieved on: 
Tuesday, August 8, 2023
Partnership, EMR, PEMS, Innovation system, Journal, Endovascular aneurysm repair, AAA, Patient, RWE, FIH, AI, Phase, FDA, IND, Medical device, Medical imaging, Pharmaceutical industry

KIRKLAND, Wash., Aug. 8, 2023 /PRNewswire-PRWeb/ -- Astute Imaging, a leading provider of AI imaging solutions for the healthcare industry, has announced a strategic agreement with Nectero Medical, the developer of the innovative Nectero EAST® (Endovascular Aneurysm Stabilization Treatment) System. Under this partnership, Nectero Medical will utilize Astute Imaging's cutting-edge imaging technologies in its Phase II/III clinical trial for the treatment of small- to mid-sized abdominal aortic aneurysms (AAA).

Key Points: 
  • Under this partnership, Nectero Medical will utilize Astute Imaging's cutting-edge imaging technologies in its Phase II/III clinical trial for the treatment of small- to mid-sized abdominal aortic aneurysms (AAA).
  • "Astute Imaging and Nectero Medical have been longstanding partners, with Astute Imaging providing advanced imaging services for Nectero Medical's Phase I clinical trial outside the US.," said Wael Elseaidy, Ph.D., CEO of Astute Imaging.
  • "We are thrilled about Nectero Medical's FDA clearance for their IND application to initiate a Phase II/III clinical trial of the Nectero EAST System to treat small-to-mid-sized AAA.
  • "Astute Imaging's AI-driven, image-based RWE platform is a major, disruptive technology for medical device companies, enabling near real-time visibility of implanted device performance," said Ewad De Vries, CTO of Astute Imaging.

New Data Shows Advantages of Rapid Medical’s COMANECI™ Embolization Assist Device

Retrieved on: 
Wednesday, July 19, 2023
Research, Medical Devices, Surgery, Neurology, Other Health, Biotechnology, General Health, Health, Science, Other Science, Medicine, University, Endovascular aneurysm repair, World Neurosurgery, Anatomy, Vasospasm, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Buffalo, Stroke, BAC, Meta-analysis, Doctor of Philosophy, Jacobs Institute for Design Innovation, Subarachnoid hemorrhage, Thrombosis, MD, Patient, Neurosurgery, Bleeding, SAC, George Washington University, Medical device

Rapid Medical ™, a leading developer of advanced neurovascular devices, today announced new clinical data showing significant advantages of its novel COMANECI™ embolization assist device over established techniques to treat ruptured wide-neck intracranial aneurysms.

Key Points: 
  • Rapid Medical ™, a leading developer of advanced neurovascular devices, today announced new clinical data showing significant advantages of its novel COMANECI™ embolization assist device over established techniques to treat ruptured wide-neck intracranial aneurysms.
  • “The COMANECI device is a highly useful adjunct tool for patients with subarachnoid hemorrhage.
  • It has been used in over 12,000 procedures worldwide in wide-neck aneurysm treatments–and in Europe only–to open arteries constricted by vasospasm.
  • However, COMANECI-assisted coiling showed significantly lower thromboembolic and aneurysmal complication rates and periprocedural complications–than both SAC and BAC.

Marizyme, Inc.: Marizyme Announces IP Developments for DuraGraft® and its Pipeline of Products

Retrieved on: 
Wednesday, May 10, 2023
LLP, CE, Chronic kidney disease, Private law, Creatinine, Endovascular aneurysm repair, Enzyme, Burn, IP, Incidence, Ischemia, Patent, Epithelium, Growth, Dentons, Skin, Disease, Pharmaceutical industry

The issued patents and allowed patent applications protect DuraGraft, a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries.

Key Points: 
  • The issued patents and allowed patent applications protect DuraGraft, a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries.
  • DuraGraft is the only approved product to preserve and protect vascular grafts during bypass and other vascular surgeries.
  • The patent application relates to a method for mixing two reagents to produce a detectable reaction in a microfluidic chip.
  • Dentons has been consistently ranked for the past years as a top leading life sciences and health care law firm.

Rapid Medical Marks First Procedures with Numen™ Coil from MicroPort Scientific

Retrieved on: 
Tuesday, June 28, 2022
Science, Neurology, Other Science, Biotechnology, Research, Health, Medical Devices, Clinical Trials, FDA, World Neurosurgery, Patient, Endovascular aneurysm repair, MicroPort, Anatomy, Stroke, Medicine, Aneurysm, Mortality, De novo, Partnership, CE, XL, Grand Rapids Medical Mile, Â, Physician, Medical imaging

Rapid Medical , a leading developer of advanced neurovascular devices, announces the expansion of its portfolio in the United States and the first Numen coil embolization procedure.

Key Points: 
  • Rapid Medical , a leading developer of advanced neurovascular devices, announces the expansion of its portfolio in the United States and the first Numen coil embolization procedure.
  • Rapid Medical now has an exclusive distribution agreement with MicroPort NeuroTech, a subsidiary of MicroPort Scientific Corporation.
  • The Numen Coil Embolization System showed excellent results in a 350-patient, prospective head-to-head study against one of the market-leading coils1.
  • We are excited to expand our portfolio for treating brain aneurysms with the addition of the Numen Coil Embolization System, comments James Romero, President, Americas of Rapid Medical.

Thoracic Aortic Stent Grafts Pipeline Insights and Competitive Landscape Report 2022: Brand Positioning of Leading Companies, Application, Industry Collaborations - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 31, 2022
Health, Cardiology, Nexus, NEXUS, Heart, Sale, EVAR, Smoking, Aortic dissection, Cook Group, Bentall procedure, Growth, Competitive landscape, Patient, CVD, Vein, Medtronic, Time-invariant system, CT, Incidence, Northwell Health, Safety, Anatomy, Acquisition, Degenerative disease, Physician, Aortic arch, News, OSR, Interrupted aortic arch, Aortic aneurysm, FDA, Aneurysm, Blood, PMA, Endovascular aneurysm repair, Oil, Medical device

The "Thoracic Aortic Stent Grafts-Pipeline Insight and Competitive Landscape, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thoracic Aortic Stent Grafts-Pipeline Insight and Competitive Landscape, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Thoracic Aortic Stent Grafts-Pipeline Insight and 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Thoracic Aortic Stent Grafts pipeline landscape.
  • This report provides a detailed study of the emerging Thoracic Aortic Stent Grafts devices along with competitive landscape to help better understand the emerging Thoracic Aortic Stent Grafts devices.
  • Thoracic Aortic Stent Grafts can be divided based on Treatment Types - Open Surgical Repair (OSR), Endovascular Aneurysm Repair (EVAR), Abdominal Aortic Aneurysm Repair, Thoracic Aortic Aneurysm Repair & Thoracic Endovascular Aneurysm Repair.

Branched Stent Grafts Market Size To Reach $477.5 Million By 2028: Grand View Research, Inc.

Retrieved on: 
Wednesday, July 28, 2021
Medical specialties, Angiology, Cardiovascular system, Vascular diseases, Vascular surgery, Interventional radiology, Thoracic aortic aneurysm, Aneurysm, Aortic aneurysm, Stent, Gustavo S. Oderich, Endovascular aneurysm repair

SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.
  • In addition, the preference for endovascular treatment for aortic aneurysms further boosts the market growth.
  • Thoracic aortic aneurysm and AAA are types of aortic aneurysms; aneurysms can also occur in other parts of the body.
  • Grand View Research has segmented the global branched stent grafts market on the basis of type, application, and region:
    Branched Stent Grafts Type Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)
    Branched Stent Grafts Application Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)

Branched Stent Grafts Market Size To Reach $477.5 Million By 2028: Grand View Research, Inc.

Retrieved on: 
Wednesday, July 28, 2021
Medical specialties, Angiology, Cardiovascular system, Vascular diseases, Vascular surgery, Interventional radiology, Thoracic aortic aneurysm, Aneurysm, Aortic aneurysm, Stent, Gustavo S. Oderich, Endovascular aneurysm repair

SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.
  • In addition, the preference for endovascular treatment for aortic aneurysms further boosts the market growth.
  • Thoracic aortic aneurysm and AAA are types of aortic aneurysms; aneurysms can also occur in other parts of the body.
  • Grand View Research has segmented the global branched stent grafts market on the basis of type, application, and region:
    Branched Stent Grafts Type Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)
    Branched Stent Grafts Application Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)

Endovascular Aneurysm Repair (EVAR) Market Report 2021: Global Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2015-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Hospitals, Pharmaceutical, Health, Medical specialties, Angiology, Cardiovascular system, Vascular surgery, Vascular diseases, Interventional radiology, Endovascular aneurysm repair, Evar, Aneurysm, Neurosurgery, Open aortic surgery, Aortic aneurysm

The "Endovascular Aneurysm Repair (EVAR) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Endovascular Aneurysm Repair (EVAR) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global endovascular aneurysm repair market exhibited moderate growth during 2015-2020.
  • Looking forward, the global endovascular aneurysm repair market to grow at a CAGR of around 5% during the forecast period (2021-2026).
  • Due to the prevalence of aneurysms, along with the growing geriatric population, endovascular treatment is increasingly being adopted by healthcare providers.

Endologix LLC Announces Launch of ALTO® Abdominal Stent Graft System in Canada and Argentina

Retrieved on: 
Tuesday, May 11, 2021
Health, Surgery, Cardiology, Medical devices, Interventional radiology, Medical specialties, Vascular surgery, Medicine, Endovascular aneurysm repair, Clinical medicine, Evar, Stent, XC2, Abdominal Aortic Aneurysm (AAA), the ALTO Abdominal Stent Graft System, Endologix’s Product Portfolio, Endologix, ABDOMINAL AORTIC ANEURYSM (AAA), THE ALTO ABDOMINAL STENT GRAFT SYSTEM, ENDOLOGIX’S PRODUCT PORTFOLIO, ENDOLOGIX

b"Endologix LLC , a leader in the treatment of vascular disease, today announced the first implant of its ALTO\xc2\xae Abdominal Stent Graft in Canada following recent approval from Health Canada.

Key Points: 
  • b"Endologix LLC , a leader in the treatment of vascular disease, today announced the first implant of its ALTO\xc2\xae Abdominal Stent Graft in Canada following recent approval from Health Canada.
  • View the full release here: https://www.businesswire.com/news/home/20210511005366/en/\nFeaturing a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation in polymer-based therapies for AAA patients.
  • ALTO utilizes a low-profile delivery system and, unlike standard EVAR devices, features an exclusive conformable sealing ring that molds in-situ to the patient\xe2\x80\x99s specific aortic neck anatomy.
  • The company\xe2\x80\x99s current commercial EVAR products include the AFX\xc2\xae2 device and the ALTO\xc2\xae Abdominal Stent Graft System.